The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
December 23rd 2024
Exercise interventions may help manage chemotherapy-induced peripheral neuropathy (CIPN) in patients with ovarian cancer through improved physical activity and muscle function, but evidence remains limited.
Vyvgart Phase 3 Extension Study Data Affirm Long-Term Safety, Efficacy in gMG
February 15th 2024Details from the final interim data analysis of the ADAPT+ study confirm previous findings seen with efgartigimod (Vyvgart) in generalized myasthenia gravis (gMG), the rare neuromuscular autoimmune disease.
Read More
The Federal Trade Commission and HHS will examine generic drug shortage causes; the Biden administration recently dedicated an additional $515 million to a major initiative to study long COVID; cybersecurity experts warn that US hospitals are at risk for attacks and the government is doing little to prevent such breaches.
Read More
In Adolescents With Obesity, FMT Shows No Negative Impact on Horizontal Gene Transfer
February 15th 2024For this analysis, investigators used metagenomic sequencing files from the Gut Bugs trial, a placebo-controlled multidonor fecal microbiota transplantation (FMT) trial conducted among adolescents classified as obese.
Read More
Registry Reveals Sex Differences in HoFH Diagnosis, Treatment, and Cardiovascular Outcomes
February 15th 2024Although the prevalence of myocardial infarction (MI) was doubled among men compared with women with homozygous familial hypercholesterolemia (HoFH), both sexes had similar ages at first MI.
Read More
Nutritional Intervention May Improve Outcomes but Is Underresearched in Ovarian Cancer
February 14th 2024A recent review suggests patients diagnosed with ovarian cancer may benefit from nutritional intervention as part of disease management, but research on the topic has been limited and further investigation is warranted.
Read More
Bundling Interventions to Promote CRC, SDOH Screenings Found Feasible, Effective
February 14th 2024Combining interventions to encourage screenings for colorectal cancer (CRC) and social determinants of health (SDOH) was found to improve screening rates in CRC without decreasing rates of screenings for SDOH.
Read More
Part of the recent Medicare reimbursement cuts could be addressed in a spending package next month; Medicaid/Medicare dual eligibles are expected to generate big profits for health insurers; FDA sent warning letters to online vendors selling unapproved and misbranded versions of semaglutide and tirzepatide.
Read More
Durvalumab Consolidation Therapy Shows Promise in Elderly Patients With Stage III NSCLC
February 12th 2024Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.
Read More
Meta-Analysis Highlights Differing CAR T Outcomes, Toxicities in Relapsed or Refractory DLBCL
February 12th 2024A real-world comparison of 2 chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel and tisagenlecleucel—suggests the former is associated with better efficacy but higher toxicity.
Read More
Primary Care Diabetes Management May Also Reduce Risk of Dementia
February 12th 2024Participants in the Risk Assessment and Management Program-Diabetes Mellitus had reduced risks of developing all-cause dementia by 28%, Alzheimer disease by 15%, vascular dementia by 39%, and other or unspecified dementia by 29%.
Read More
Camilla Levister on the Benefits of Artificial Pancreas Systems for Type 1 Diabetes
February 12th 2024Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, discusses how closed-loop systems benefit patients managing type 1 diabetes.
Watch
Dr Ann LaCasce Discusses Potentially Game-Changing Treatments for Lymphoma
February 11th 2024Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s scientific advisory board, discussed the changing lymphoma treatment landscape and highlighted potentially game changing treatments.
Watch
In-House Biomarker Testing Shortens Time to Treatment Decision for mNSCLC
February 9th 2024This retrospective analysis compared molecular testing outcomes among newly diagnosed cases of metastatic non–small cell lung cancer (mNSCLC) from 2 periods: March 2017 to May 2019 and July 2019 to March 2021.
Read More
15-Year Analysis Shows Decrease in Ovarian Cancer Incidence, Incidence-Based Mortality
February 9th 2024The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with epithelial cancer, especially in advanced stages.
Read More